natriuretic-peptide--brain and Lung-Diseases--Obstructive

natriuretic-peptide--brain has been researched along with Lung-Diseases--Obstructive* in 10 studies

Other Studies

10 other study(ies) available for natriuretic-peptide--brain and Lung-Diseases--Obstructive

ArticleYear
Response to "Getting the right message".
    Annals of emergency medicine, 2007, Volume: 49, Issue:3

    Topics: Biomarkers; Clinical Trials as Topic; Heart Failure; Humans; Lung Diseases, Obstructive; Natriuretic Peptide, Brain; Peptide Fragments; Research Design

2007
On "Getting the right message".
    Annals of emergency medicine, 2007, Volume: 49, Issue:3

    Topics: Biomarkers; Cost-Benefit Analysis; Diagnostic Techniques, Cardiovascular; Heart Failure; Humans; Lung Diseases, Obstructive; Natriuretic Peptide, Brain; Peptide Fragments; Research Support as Topic

2007
Getting the right message: avoiding overly optimistic interpretations of the scientific literature.
    Annals of emergency medicine, 2006, Volume: 48, Issue:1

    Topics: Aged; Biomarkers; Dyspnea; Heart Failure; Humans; Information Dissemination; Lung Diseases, Obstructive; Marketing; Natriuretic Peptide, Brain; Peptide Fragments; Periodicals as Topic

2006
Chronic beneficial effects of type 1 angiotensin II receptor antagonist in patients with chronic hypoxemic pulmonary diseases.
    Cardiology, 2002, Volume: 97, Issue:2

    Topics: Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Natriuretic Factor; Female; Humans; Losartan; Lung Diseases, Obstructive; Male; Middle Aged; Natriuretic Peptide, Brain

2002
Plasma endothelin-1 level in chronic obstructive pulmonary disease: relationship with natriuretic peptide.
    Respiration; international review of thoracic diseases, 1999, Volume: 66, Issue:3

    Endothelin-1 (ET-1) is a potent vasoconstrictor peptide produced by the vascular endothelium. The purpose of this study was to elucidate the pathophysiological role of ET-1 in patients with pulmonary hypertension secondary to chronic obstructive pulmonary disease (COPD).. We measured plasma ET-1 levels during right heart catheterization both at rest and during exercise on room air and while breathing oxygen in patients with COPD. In addition, we simultaneously measured plasma levels of atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP).. Plasma ET-1 levels at rest were significantly higher in 21 patients with COPD than in 16 control subjects (p < 0.001). For COPD patients, there was no correlation between the plasma ET-1 level and pulmonary arterial pressure or pulmonary vascular resistance at rest. On the other hand, there was a significant negative correlation between plasma ET-1 level and mixed venous oxygen tension (r = -0. 503, p < 0.05). Also, the plasma ET-1 level was positively correlated with those of ANP (r = 0.540, p < 0.05) and BNP (r = 0. 533, p < 0.05) at baseline. Oxygen administration significantly decreased plasma ET-1 levels at rest (p < 0.05). Plasma ET-1 levels did not change significantly with exercise despite the progression of pulmonary hypertension and hypoxemia. In contrast, plasma ANP and BNP levels both increased markedly with exercise (p < 0.01).. We conclude that in patients with COPD, the plasma ET-1 level is not affected by acute progression of pulmonary hypertension and hypoxemia during exercise, and persistent hypoxemia may be associated with an increase in the plasma ET-1 level. In addition, our findings suggest that ANP and BNP may modulate the pulmonary vascular tone by interacting with ET-1 in these patients.

    Topics: Aged; Atrial Natriuretic Factor; Endothelin-1; Exercise; Humans; Hypoxia; Lung Diseases, Obstructive; Male; Middle Aged; Natriuretic Peptide, Brain; Reference Values

1999
Elevated plasma brain natriuretic peptide levels in chronic respiratory failure with cor pulmonale.
    Respiratory medicine, 1999, Volume: 93, Issue:7

    Elevated plasma brain natriuretic peptide (BNP) levels have been described in patients with congestive heart failure and acute myocardial infarction. We measured plasma BNP levels in patients with chronic respiratory failure to evaluate the correlation between plasma BNP levels and pulmonary haemodynamics. Plasma BNP levels were measured in 28 patients with chronic respiratory failure accompanied by three underlying diseases [14 with chronic obstructive pulmonary disease (COPD), seven with sequelae of pulmonary tuberculosis (sequelae Tbc) and seven with diffuse panbronchiolitis (DPB)] by immunoradiometric assay methods (IRMA). Twenty-one of 28 patients had already received oxygen supplementation and 16 of 21 patients were treated as outpatients with home oxygen therapy. Plasma BNP levels were significantly elevated in patients with chronic respiratory failure complicated by cor pulmonale (81.5 +/- 13.1 pg ml-1) compared to patients without cor pulmonale (13.3 +/- 2.7 pg ml-1, P < 0.001). As controls, plasma BNP levels in 10 patients with primary lung cancer were studied, and the results (3.5 +/- 1.0 pg ml-1) were not significantly different from those of patients with chronic respiratory failure without cor pulmonale. Plasma BNP levels in 12 healthy subjects were also studied, and the results (7.2 +/- 1.0 pg ml-1) were not significantly different from those of the control subjects. Plasma BNP levels showed a weak linear correlation with systolic pulmonary arterial blood pressure, estimated by Doppler echocardiography (r = 0.43; P = 0.068), but there was no significant correlation between BNP levels and the degree of hypoxaemia (r = 0.30; P = 0.138). Plasma atrial natriuretic peptide (ANP) levels in patients with chronic respiratory failure were also measured using the same samples. Plasma ANP levels were also significantly elevated in patients with chronic respiratory failure complicated by cor pulmonale (80.8 +/- 12.1 pg ml-1) compared to patients without cor pulmonale (26.1 +/- 4.4 pg ml-1, P = 0.003). A significant correlation was found between plasma BNP and ANP levels (r = 0.68; P < 0.001). Our results suggest that the plasma BNP or ANP level may be a useful indicator for detecting the presence of cor pulmonale in patients with chronic respiratory failure.

    Topics: Adult; Aged; Aged, 80 and over; Atrial Natriuretic Factor; Female; Humans; Immunoradiometric Assay; Lung Diseases, Obstructive; Male; Middle Aged; Natriuretic Peptide, Brain; Pulmonary Heart Disease; Respiratory Insufficiency

1999
The natriuretic peptides. Clinical applications in patients with COPD.
    Chest, 1996, Volume: 110, Issue:5

    Topics: Atrial Natriuretic Factor; Blood Pressure; Gene Expression Regulation; Guanylate Cyclase; Humans; Hypertension, Pulmonary; Hypoxia; Lung Diseases, Obstructive; Natriuretic Peptide, Brain; Natriuretic Peptide, C-Type; Nerve Tissue Proteins; Proteins; Receptors, Atrial Natriuretic Factor; Up-Regulation; Vascular Resistance; Vasodilator Agents

1996
Plasma levels of atrial natriuretic peptide and brain natriuretic peptide following intravenous saline infusion in oedematous chronic obstructive pulmonary disease and non-oedematous chronic obstructive pulmonary disease.
    Respiration; international review of thoracic diseases, 1996, Volume: 63, Issue:6

    Some patients with chronic obstructive pulmonary disease (COPD) develop oedematous COPD (oCOPD) with peripheral oedema and have a poor prognosis. The cause of the fluid retention is poorly understood but could be due to defective release of a natriuretic factor. We investigated this hypothesis by measuring levels of brain natriuretic peptide (BNP) and atrial natriuretic peptide (ANP) before and after a 0.1 ml/kg/min 2.7% saline infusion in 6 patients with hypoxemic COPD but no history of oedema and 7 COPD patients with oCOPD. Vasopressin, aldosterone, plasma and urinary urea and electrolytes and osmolality were measured. Arterial blood gases and spirometry were also recorded. The two groups were similar in terms of age, weight, PaO2, PaCO2 and FVC. FEV1 was significantly lower in the oCOPD group. The oCOPD group excreted less urine (202 +/- 23 vs. 364 +/- 48 ml; p < 0.05) and less sodium (32 +/- 3 vs. 68 +/- 9 mmol/l; p < 0.01) as a percentage of the saline load given (18 +/- 2 vs. 30 +/- 4%; p < 0.05). Pre-infusion BNP and ANP levels were similar in both groups. BNP and ANP had an exaggerated increase in the oCOPD group on saline loading. In the oCOPD group, ANP levels were significantly greater 1 h after the saline load compared to the pre-infusion values (30 +/- 7 vs. 11 +/- 2; p < 0.05). BNP did not reach significantly greater levels than baseline values until 3 h after the infusion had ended (45 +/- 6 vs. 27 +/- 2; p < 0.05). At 1 h after the saline load, BNP and ANP levels were significantly greater in the oCOPD group (BNP 32 +/- 2 vs. 24 +/- 1; p < 0.01 and ANP 30 +/- 7 vs. 7 +/- 2; p < 0.05) when compared to COPD controls. BNP levels remained significantly different from the COPD control group 3 h after the infusion ended (45 +/- 6 vs. 26 +/- 2; p < 0.05). Although aldosterone levels were greater in the oCOPD group before the saline infusion, the hormone level was suppressed appropriately by the infusion. In conclusion, the cause of oedema in oCOPD and the inability to excrete a saline load is not due to a failure of release of BNP or ANP.

    Topics: Aged; Aldosterone; Analysis of Variance; Atrial Natriuretic Factor; Edema; Humans; Lung Diseases, Obstructive; Natriuretic Peptide, Brain; Nerve Tissue Proteins; Prognosis; Sodium; Sodium Chloride

1996
Measurement of plasma brain natriuretic peptide in heart failure.
    Lancet (London, England), 1994, Apr-02, Volume: 343, Issue:8901

    Topics: Dyspnea; Heart Failure; Humans; Lung Diseases, Obstructive; Natriuretic Peptide, Brain; Nerve Tissue Proteins

1994
Elevated levels of brain natriuretic peptide in acute hypoxaemic chronic obstructive pulmonary disease.
    Clinical science (London, England : 1979), 1992, Volume: 83, Issue:5

    1. Studies in vitro have recently shown that both atrial natriuretic peptide and brain natriuretic peptide have pulmonary vasorelaxant activity. The purpose of the present study was to evaluate for the first time whether plasma levels of brain natriuretic peptide are elevated in chronic obstructive pulmonary disease. Plasma levels of brain natriuretic peptide and atrial natriuretic peptide were therefore measured in 12 patients admitted with acute hypoxaemic chronic obstructive pulmonary disease [arterial partial pressure of O2, 6.2 +/- 0.4 kPa; arterial partial pressure of CO2, 6.9 +/- 0.1 kPa; forced expiratory volume in 1 s, 0.6 +/- 0.07 litre (27 +/- 3% of predicted)]. All but three patients had oedema on admission. 2. Plasma levels of both brain natriuretic peptide and atrial natriuretic peptide were elevated in patients with chronic obstructive pulmonary disease (31.4 +/- 4.1 pmol/l and 45.0 +/- 8.1 pmol/l, respectively) compared with healthy control subjects (1.7 +/- 0.8 pmol/l and 8.0 +/- 3.5 pmol/l, respectively). Thus, plasma levels of brain natriuretic peptide and atrial natriuretic peptide in patients with chronic obstructive pulmonary disease were increased by 18.5- and 5.6-fold respectively compared with healthy control subjects. 3. There was a significant inverse correlation between the plasma level of brain natriuretic peptide and the arterial partial pressure of O2 (r = -0.65, r2 = 0.42, P = 0.03), but not between the plasma atrial natriuretic peptide level and the arterial partial pressure of O2 (r2 = 0.07, not significant). The arterial partial pressure of CO2 did not correlate with the plasma level of either brain natriuretic peptide or atrial natriuretic peptide.(ABSTRACT TRUNCATED AT 250 WORDS)

    Topics: Acute Disease; Aged; Atrial Natriuretic Factor; Female; Humans; Hypoxia; Lung Diseases, Obstructive; Male; Natriuretic Peptide, Brain; Nerve Tissue Proteins; Oxygen

1992